Suven’s products gets three patent grants; from Canada, ARIPO, and South Korea
January 5, 2016Suven Life Sciences Ltd has announced that the grant of one product patent from Canada, one from ARIPO and one from South Korea corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.
As Suven explained Tuesday, the granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive imparirment associated with neurodegenerative disorders like Alzheimer’s disease, Attendion deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schiziphrenia.
With these new patents, as Suven says, the company has a total of twenty one granted patents from Canada, two from ARIPO and nineteen from South Korea.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally”, said Venkat Jasti, CEO of Suven.